In early March, as the coronavirus was spreading across the United States and testing capacity was already a problem, Bill Phillips had an idea.
Phillips is the chief operating officer of a medical device company, Spectrum Solutions, that provides saliva test kits for companies like Ancestry.com. He wondered if Spectrum’s kits — which require customers to spit in a tube and ship their samples through the mail — could work with detecting this new virus.
“I just threw it out there: Why don’t we test our device to see if we can use it as a transport medium to get it to the lab?” Phillips recalled in a recent telephone interview.
Spectrum, based outside Salt Lake City, teamed up with a laboratory at Rutgers University, made a few tweaks and found that the effectiveness of their saliva test kit was comparable to the nasopharyngeal test, or the long swab, that was already in widespread use.
By mid-April, the Food and Drug Administration granted the Rutgers lab an emergency-use authorization. A month later, it received approval for the test kit to be used at home.
That saliva kit is now a key part of Major League Baseball’s plan to return to play, and has also been used by other revived sports leagues, including the PGA Tour and Major League Soccer.
With sports leagues desperate to salvage their seasons and profits, testing was always crucial — even more so now as the number of cases rises nationwide. But there was no blueprint, so a patchwork of businesses and labs, all with entirely different missions before the pandemic, converged to meet the need.
A version of Spectrum’s spit test, once used to help figure out family trees, is now spotting infections. Vault Health, a telehealth company that was focused on sexual health and weight-loss therapies for men, is now using Spectrum’s saliva kit and the Rutgers lab to help leagues conduct wide-scale testing. And the Sports Medicine Research and Testing Laboratory in Utah, which previously handled antidoping testing for MLB, is now processing coronavirus saliva tests for the league.
Dr. Daniel Eichner, president and laboratory director of SMRTL, the shorthand name for the Utah lab doing MLB’s coronavirus testing, acknowledged that there was “nothing good about this virus.” But, he said, he was proud of his team’s ability to pivot to this new challenge, like other companies.
“It’s a beautiful American story: When the chips are down, people jump in to contribute as best they can,” Eichner said.
Navigating the rapidly evolving world of coronavirus testing has been far from a simple task for professional sports leagues. They have had to weigh the efficacy and speed of various tests and companies, all while trying to ensure they would not be taking away resources from those who needed them more.
“It was incredibly complicated,” said Andy Levinson, the PGA Tour’s senior vice president of tournament administration.
When leagues began exploring their options — Levinson said the tour consulted laboratory directors and its own medical advisers — saliva-based tests emerged as a popular choice. They could be done almost anywhere, with minimal assistance from a medical professional and without much personal protective equipment, and some studies found saliva was a reliable alternative to the more-common nasopharyngeal swabs.
Another benefit: Spitting in a tube is much less painful than a swab shoved deep into the nasal cavity.
“We call it the brain tickler,” said Jason Feldman, chief executive of Vault Health.
Feldman’s company is now a linchpin for several leagues’ coronavirus testing operations. Before the pandemic, it was part of a growing wave of telehealth companies, connecting patients with doctors via video calls and facilitating shipments of treatments through the mail.
When the pandemic hit the U.S., Feldman, like many business owners, feared the potential economic effects on his company. But then he realized he was sitting on a wealth of resources that would be useful amid the crisis: He had a relationship with both the Rutgers lab, known as RUCDR Infinite Biologics, and Spectrum Solutions for other products, and a virtual consultation platform that would provide a safe way to talk to patients.
Vault Health devised an at-home saliva testing package, which is supervised via a Zoom video call and mailed overnight to the Rutgers lab, that could produce a result within 48 to 72 hours. It costs $150 out of pocket.
“When sports leagues started calling us,” Feldman said, “they said almost universally, ‘We have athletes who want to come back to practice and we need a plan that could safely bring them back.’”
While Feldman said sports leagues make up a small percentage of his company’s testing clientele, he said Vault had supplied tests to the PGA, LPGA, MLS, and NHL, as well as a small portion of the NBA’s testing operation. A MLS spokesman said Vault had provided testing for 13 teams during training, while BioReference Laboratories would do so at the league’s restricted-site tournament that recently began outside Orlando, Florida.
An NHL spokesman said the league wasn’t prepared to disclose its testing company, and the NBA did not respond to a request seeking comment.
The PGA Tour, which had restarted competition in mid-June in Texas, was the first professional sports organization to hire Vault, Feldman said. Levinson, the tour executive, said the saliva test was basically used to approve travel: Golfers and caddies take the test before heading to an event, and then once again on the Saturday of a tournament to determine if they can board the tour’s charter plane on Monday to the next event.
But the tour needed a speedier solution for on-site testing to monitor individuals’ health during the events without clogging up local labs. For that, Levinson said, they enlisted Sanford Health, a South Dakota company that was already a title sponsor of a PGA Tour Champions event.
Sanford Health converted leftover medical trucks into three mobile laboratories, Levinson said, which can return results from the nasopharyngeal swab test in less than two hours.
A Sudden Demand
Phillips, the Spectrum Solutions executive, said that he had talked with nearly all of the professional sports leagues in the United States, including the National Women’s Soccer League and UFC, because many compare notes.
“It was just a cascading effect,” he said. “One called me then another and another.” MLB, he said, came to him in April and was expecting to use 275,000 of his kits by the end of the year.
To meet the sudden demand, Phillips said recently that Spectrum Solutions’ factory was working around the clock to make 3.5 million saliva test kits this month. He hoped to double that number, and his staff, to about 500, by August.
Thanks to automation, Dr. Andy Brooks, chief operating officer of RUCDR, said his lab in Piscataway, New Jersey, could handle 50,000 tests per day, with more room to grow. He said they had five $2 million modules — robots, essentially — each handling about 10,000 tests, and each requiring about 25 people to run.
“We are the McDonald’s of molecular lab services,” he said. “We build a process and make it efficient.”
Throughout the pandemic, public health experts have questioned whether sports leagues were jumping to the front of the line for tests at the expense of the general population. Phillips said his company has donated kits to emergency medical workers in Utah and sold them to whoever wants them, trying to fill the void created by what he called the government’s uneven response to the pandemic.
“There’s a shortage of product, but there’s an even bigger shortage of approved labs,” he said, alluding to the FDA’s backlog in emergency-use approvals for labs that could potentially handle such tests. “If we made 100 million, we can sell 100 million.”
Unlike other leagues, MLB opted to use SMRTL, the antidoping lab in Utah, to conduct its testing. Eichner said SMRTL followed the Rutgers lab’s model for its saliva testing.
Why SMRTL, a nonprofit, morphed from an antidoping testing and research lab into one focusing mostly on coronavirus testing has to do with Eichner’s background: He has a doctorate in viral immunology from the Australian National University.
And as the coronavirus raged through the United States in March, he foresaw that the demand for antidoping testing would decrease as sports stopped, and the need for coronavirus testing would skyrocket.
“We had a lot of really good, smart scientists, a lot of good instruments and we didn’t want to sit idle,” he said, adding later, “I knew we could do this test.”
As Eichner explored ways to use SMRTL to add to the country’s testing capacity, MLB was looking for return-to-play testing. The league paid to convert SMRTL into a coronavirus testing site, Commissioner Rob Manfred has said — and luckily for SMRTL, it had moved to a new facility in early March that is three times as large as its previous site.
To test the saliva coronavirus samples, the lab also needed to clear several federal hurdles. Eichner said SMRTL — used to dealing with anonymous player samples — boosted its secure network to meet federal medical privacy laws for handling patient information. While SMRTL is awaiting formal approval from the FDA on its application for an emergency-use authorization, Eichner said, they were allowed to operate in the meantime.
But MLB’s testing got off to an uneven start as teams began formal training again this month. At least six MLB teams, including last year’s World Series participants, the Washington Nationals and the Houston Astros, canceled or postponed workouts during the first week because of delays in receiving test results. Test collectors also reportedly failed to show up in some instances.
MLB said “unforeseen delays” in shipping over the July 4 holiday weekend had affected only a limited number of results and that it had since addressed the testing issues.
Before the delays became public last weekend, Eichner explained that SMRTL had promised MLB a 24-hour turnaround on test results from the moment they receive the saliva shipments. “We’ve got no control on collection or shipping of the sample,” he said.
In the wake of those hiccups, an MLB spokesman said in a statement on Friday that a portion of its nonplayer tests were expected to be handled by the Rutgers lab, and not solely SMRTL as originally planned. The spokesman said the decision had nothing to do with SMRTL’s capacity to handle the necessary testing.
With MLB testing its players and key personnel at least twice a week, Eichner said SMRTL moved from working five days a week to every day, added at least five new people and can now process 2,000-2,500 samples a day. There are split shifts: an early morning and later start to get the results out by the evening.
“All that bureaucratic stuff was the hard stuff,” he said. “The actual science was really easy for us.”
